ViroPharma surges on buyout; Transocean gains
UPDATE: Dow sights on latest in series of record highs
UPDATE: Google edges lower; Twitter reverses earlier loss
Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...